Latest news with #BioTechne
Yahoo
3 days ago
- Business
- Yahoo
Key Market Players Paving the Way for Advancements in Exosome-Based Diagnostics and Therapeutics
The global exosome research market is anticipated to expand from USD 214.4 million in 2025 to USD 480.6 million by 2030, at a CAGR of 17.5%. This growth is driven by the rising need for advanced diagnostics due to the prevalence of chronic diseases like cancer and neurodegenerative disorders. Exosomes, serving as biomarkers and therapeutic delivery agents, fulfill this demand. The kits & reagents segment is expected to lead growth, aligning with the increased demand for efficient exosome research tools. North America is projected to experience the highest growth, thanks to significant government investments supporting research initiatives. Key players such as Thermo Fisher Scientific and Bio-Techne are profiled. Exosome Research Market Dublin, July 18, 2025 (GLOBE NEWSWIRE) -- The "Exosome Research Market by Offering (Kits, Reagents (Antibodies, Isolation, Purification), Instruments, Services), Indication (Cancer, Infectious Diseases), Application (Biomarkers, Vaccines), Manufacturing Services (Stem Cell) - Global Forecast to 2030" report has been added to global exosome research market is projected to reach USD 480.6 million by 2030 from USD 214.4 million in 2025, at a CAGR of 17.5% during the forecast period. The report will help market leaders and new entrants by providing them with the closest approximations of the revenue numbers for the overall exosome research market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their businesses and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges. The expansion of the exosome research market is primarily fueled by the escalating incidence of chronic diseases, including cancer, neurodegenerative disorders, and CVDs; this trend underscores the urgent need for novel diagnostic and therapeutic strategies. Exosomes, due to their properties as potential biomarkers and their capacity to facilitate targeted therapeutic delivery, are uniquely positioned to address the increasing demand for advanced disease diagnostics and treatment modalities. The kits & reagents segment is expected to grow at the highest CAGR during the study academic institutions, biotechnology companies, and diagnostic developers delve deeper into the multifaceted roles of exosomes in disease diagnostics and therapeutic interventions, there has been a notable increase in the demand for standardized, user-friendly kits & reagents. These specialized tools play a crucial role in simplifying and expediting the workflows associated with exosome isolation, purification, labeling, and downstream analysis. Exosomes, nano-sized vesicles secreted by cells, have emerged as significant biomarkers in various diseases, necessitating precise handling and standardization offered by commercially available kits helps ensure that researchers can perform these tasks with consistency and reliability, which is vital in both translational research and preclinical development. In particular, reproducibility is critical in scientific research; utilizing validated kits ensures consistent protocols that minimize variability and enhance overall research outcomes. This reliability is particularly pertinent in biomarker discovery and liquid biopsy research, where the identification of accurate biomarkers is paramount for early disease detection and the growing interest in exosome-based diagnostics - especially within oncology for cancer detection and neurodegenerative diseases like Alzheimer's and Parkinson's - laboratories are increasingly opting for ready-to-use reagent systems. These systems facilitate sample preparation, RNA and DNA extraction, and comprehensive cargo profiling, thereby supporting a range of downstream molecular applications. The integration of such standardized tools not only streamlines the research process but also enhances the quality of data generated, ultimately contributing to the advancement of exosome research in clinical settings. As the landscape of diagnostics continues to evolve, the role of such reliable and efficient kits will become even more pronounced, paving the way for breakthroughs in personalized medicine and targeted America is expected to grow at the highest CAGR in the global exosome research market from 2025 to America maintains its leading position in the global exosome research market, primarily due to substantial government investment and support mechanisms. Key organizations such as the National Institutes of Health (NIH) in the United States are pivotal, channeling significant funding into biomedical research, specifically targeting projects centered on exosomes. This financial endorsement empowers researchers to explore novel applications of exosomes in both diagnostics and therapeutics. For example, in June 2024, the National Heart, Lung, and Blood Institute (NHLBI) renewed a USD 12 million Program Project Grant (PPG) to support researchers at the Lewis Katz School of Medicine at Temple investigation focuses on heart cell-derived exosomes and their involvement in cardiac injury and repair processes. This funding facilitates a deeper understanding of the mechanisms by which exosomes contribute to myocardial tissue regeneration, potentially leading to groundbreaking therapeutic strategies. Likewise, in August 2023, the National Cancer Institute (NCI) allocated USD 2.5 million to the Sylvester Comprehensive Cancer Center to advance research on exosome-based biomarkers for prostate cancer detection through urine and blood assays. Such robust government backing not only propels scientific exploration but also fosters collaboration between academic institutions and industry, thereby cultivating a dynamic research ecosystem. This well-capitalized environment accelerates innovation and reinforces North America's status as a frontrunner in exosome research. As a result, the region continues to draw in investments and talent, driving ongoing growth within the exosome research report provides insights on the following pointers: Analysis of key drivers (increasing investment in pharmaceutical & life sciences research, rising cancer prevalence, and increasing interest in exosome-based procedures), restraints (technical complexity of exosome isolation, and regulatory uncertainty in exosome research), opportunities (rising investments in emerging countries for exosome research, growing interest in exosome-based therapeutics, and increasing demand for personalized medicines), and Challenges (lack of gold standard protocols for exosome development and production and limited understanding of cargo loading). Product Development/Innovation: Detailed insights on upcoming products, research and development activities, and new product approvals/launches in the exosome research market. Market Development: Comprehensive information about lucrative markets; the report analyses the market across varied regions. Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the exosome research market. Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players. A detailed analysis of the key industry players has been done to provide insights into their key strategies, product launches/ approvals, acquisitions, partnerships, agreements, collaborations, other recent developments, investment and funding activities, brand/product comparative analysis, and vendor valuation and financial metrics of the exosome research market. Key Attributes: Report Attribute Details No. of Pages 325 Forecast Period 2025 - 2030 Estimated Market Value (USD) in 2025 $214.4 Million Forecasted Market Value (USD) by 2030 $480.6 Million Compound Annual Growth Rate 17.5% Regions Covered Global Companies Featured Thermo Fisher Scientific Inc. Qiagen Lonza Danaher Bio-Techne System Biosciences, LLC Amsbio Roosterbio, Inc. Miltenyi Biotec Norgen Biotek Corp. Aethlon Medical, Inc. Creative Medical Technologies Holdings, Inc. Spectris Nanofcm, Inc. Izon Science Limited Capricor Therapeutics, Inc. Anjarium Biosciences AG Ciloa Innovaprep Ilias Biologics Inc. Unchained Labs Rion Inc. Cell Guidance System LLC Inoviq Nx Pharmagen Exopharm Everzom Nanosomix Creative Biolabs For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Exosome Research Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Yahoo
3 days ago
- Business
- Yahoo
Bio-Techne's Quarterly Earnings Preview: What You Need to Know
Valued at a market cap of $8.1 billion, Bio-Techne Corporation (TECH) is a leading Minneapolis-based life sciences company that develops and supplies over 500,000 high-quality products, including reagents, diagnostic tools, and analytical instruments for research, bioprocessing, and clinical diagnostics. It is expected to announce its fiscal Q4 earnings on Wednesday, Aug. 6. Prior to this event, analysts project this biotechnology company to report a profit of $0.45 per share, down 8.2% from $0.49 per share in the year-ago quarter. The company has a promising trajectory of consistently beating Wall Street's bottom-line estimates in each of the last four quarters. More News from Barchart Insider Trading Alert: Here's Who Bought Nvidia and AMD Stock Before the U.S. Chip Deal with China Dear Tesla Stock Fans, Mark Your Calendars for July 23 As QuantumScape Hits New 2025 Highs, Should You Buy, Sell, or Hold QS Stock? Our exclusive Barchart Brief newsletter is your FREE midday guide to what's moving stocks, sectors, and investor sentiment - delivered right when you need the info most. Subscribe today! For the current year, analysts expect TECH to report EPS of $1.66, up 5.7% from $1.57 in fiscal 2024. Shares of TECH have declined 31.9% over the past 52 weeks, considerably trailing both the S&P 500 Index's ($SPX) 12.7% upstick, and the Health Care Select Sector SPDR Fund's (XLV) 11.8% loss over the same time frame. On May 7, TECH shares surged over 2% after reporting its Q3 results. The company reported robust earnings driven by solid demand across its core segments, particularly in cell and gene therapy tools, diagnostics, and proteomic solutions. Its revenue came in at $316.2 million, reflecting year-over-year growth, while adjusted earnings per share stood at $0.56, beating analyst estimates. Wall Street analysts are moderately optimistic about TECH's stock, with a "Moderate Buy" rating overall. Among 15 analysts covering the stock, ten recommend "Strong Buy," and five indicate 'Hold.' The mean price target for TECH is $64.92, which indicates a notable 21.8% potential upside from the current levels. On the date of publication, Kritika Sarmah did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Sign in to access your portfolio
Yahoo
4 days ago
- Business
- Yahoo
Bio-Techne to Host Conference Call on August 6, 2025, to Announce Fourth Quarter and Fiscal 2025 Financial Results
MINNEAPOLIS, July 17, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Wednesday, August 6, 2025, at 8:00 a.m. CDT to review its fourth quarter and fiscal 2025 financial results. Access to the discussion may be obtained as follows: Time: 8:00 a.m. CDT Date: August 6, 2025 Dial-in: 1-800-274-8461 or 1-203-518-9814 (for international callers) Conference ID: TECHQ4 Webcast: A recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 1-844-512-2921 or 1-412-317-6671 (for international callers) and referencing Conference ID 11159590. The replay will be available from 11:00 a.m. CDT on Wednesday, August 6, 2025, until 11:00 p.m. CDT on Saturday, September 6, 2025. About Bio-TechneBio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With hundreds of thousands of products in its portfolio, Bio-Techne generated approximately $1.2 billion in net sales in fiscal 2024 and has approximately 3,100 employees worldwide. For more information on Bio-Techne and its brands, please visit or follow the Company on social media at: Facebook, LinkedIn, Twitter or YouTube. Contact: David Clair, Vice President, Investor Relations & Corporate Development 612-656-4416 View original content to download multimedia: SOURCE Bio-Techne Corporation Sign in to access your portfolio
Yahoo
09-07-2025
- Business
- Yahoo
5 Revealing Analyst Questions From Bio-Techne's Q1 Earnings Call
Bio-Techne's first quarter results were met with a positive market reaction as the company delivered both organic revenue growth and adjusted profit above Wall Street expectations. Management attributed this momentum to robust demand from large pharmaceutical customers, particularly in its core reagents and protein analysis tools, as well as continued execution on cost control and operational efficiency. CEO Kim Kelderman highlighted the company's ability to manage profitability despite an uncertain macro environment, pointing to "strong execution across our product portfolio" and initiatives to drive operational efficiencies. The team noted that these gains were achieved even as the academic research market in the United States faced headwinds related to changes in federal funding policies. Is now the time to buy TECH? Find out in our full research report (it's free). Revenue: $316.2 million vs analyst estimates of $317.4 million (4.2% year-on-year growth, in line) Adjusted EPS: $0.56 vs analyst estimates of $0.51 (10.4% beat) Adjusted EBITDA: $119.1 million vs analyst estimates of $114.1 million (37.7% margin, 4.3% beat) Operating Margin: 12.2%, down from 22.1% in the same quarter last year Organic Revenue rose 5.7% year on year (2.3% in the same quarter last year) Market Capitalization: $8.26 billion While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention. Puneet Souda (Leerink Partners) asked about the impact of academic funding uncertainty and potential pull-forward in pharma orders. CFO Jim Hippel clarified that pharma growth was sustained, not the result of early demand, and academic headwinds were most pronounced after policy announcements. Dan Leonard (UBS) questioned the company's tariff exposure and manufacturing flexibility. CEO Kim Kelderman explained that regional manufacturing and supply chain adjustments largely insulated Bio-Techne from tariff impacts, especially regarding instruments and consumables exported to China. Matt Larew (William Blair) sought clarity on the sustainability of organic growth rates and margin outperformance. Hippel responded that recent margin improvements were due to disciplined cost controls, and any temporary slowdown from macro headwinds should reverse once uncertainty resolves. Daniel Markowitz (Evercore ISI) asked whether projected academic headwinds would meaningfully impact long-term growth assumptions. Hippel stated that even in severe budget cut scenarios, academic exposure is limited and the company's strategic plan still targets double-digit growth. Patrick Donnelly (Citi) inquired about trends among biotech customers and the performance of the Wilson Wolf joint venture. Kelderman noted that biotech demand was flat, reflecting sensitivity to broader capital markets, while Wilson Wolf continued to deliver solid double-digit growth. Over the next few quarters, our analyst team will be monitoring (1) clarity in NIH funding and U.S. academic research budgets, (2) the pace and effectiveness of tariff mitigation efforts on global operations, and (3) further adoption of new product platforms in organoid solutions and spatial biology. Progress in margin improvement initiatives and the performance of China and biotech customer segments will also be important indicators. Bio-Techne currently trades at $53, up from $47.64 just before the earnings. At this price, is it a buy or sell? See for yourself in our full research report (it's free). Market indices reached historic highs following Donald Trump's presidential victory in November 2024, but the outlook for 2025 is clouded by new trade policies that could impact business confidence and growth. While this has caused many investors to adopt a "fearful" wait-and-see approach, we're leaning into our best ideas that can grow regardless of the political or macroeconomic climate. Take advantage of Mr. Market by checking out our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
31-05-2025
- Business
- Yahoo
Bio-Techne Corporation (TECH): A Bull Case Theory
We came across a bullish thesis on Bio-Techne Corporation (TECH) on scuttleblurb's Substack. In this article, we will summarize the bulls' thesis on TECH. Bio-Techne Corporation (TECH)'s share was trading at $47.93 as of 28th May. TECH's trailing and forward P/E were 57.75 and 22.03 respectively according to Yahoo Finance. A close-up of a biotechnology machine working on an oncology therapy. Bio-Techne has built a diverse and complex business centered on its strong legacy in recombinant proteins, expanding downstream into antibodies, assays, and instrument platforms, while also moving into cell and gene therapy (CGT) solutions. Its revenue is split roughly between Protein Sciences and Diagnostics, which are closely linked—diagnostics identify disease biomarkers that then become therapeutic targets developed using Bio-Techne's proteins and antibodies. Despite about 20 acquisitions over the past decade, its core legacy products still contribute 56% of total revenue, with the remainder coming from faster-growing, less penetrated markets. Around half of Bio-Techne's revenue comes from commercial R&D, now dominated by smaller, venture-funded biotechs rather than big pharma, making this segment more cyclical. Academia accounts for another 20%, a price-sensitive group vulnerable to budget swings. The company is gaining ground in GMP protein production for clinical and commercial use, a highly regulated and lucrative niche, though it trails established leaders like Miltenyi and Cellgenix. Bio-Techne has also expanded into proteomics and spatial biology through acquisitions. While the company once forecasted nearly $2 billion in revenue by 2026, growth slowed due to several factors: COVID-related demand spikes followed by inventory destocking, a 20-30% revenue decline in China, fading COVID testing tailwinds, and cautious FDA oversight of CGTs that hurt growth expectations. Despite these setbacks causing a nearly 50% stock price decline, recent signs point to recovery with organic growth rebounding to 9% and instrument sales improving. Bio-Techne's broad strategy reflects its efforts to protect core franchises while expanding into new growth areas, including becoming an instrument provider to capture more downstream value. Bio-Techne Corporation (TECH) is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 34 hedge fund portfolios held TECH at the end of the first quarter which was 24 in the previous quarter. While we acknowledge the risk and potential of TECH as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than TECH but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. This article was originally published at Insider Monkey.
